Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474197 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
A Phase 2 study of Alpha-1 Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT04474197: Completed Phase 2 study of Alpha-1 Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
NCT04474197 is a Phase 2 study of Alpha-1 Antitrypsin Deficiency that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 44 participants, below the 2,340-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474197, a Phase 2 study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-864
Study Locations (20)
Florida
- University of Florida - Gainesville
- University of Miami Miller School of Medicine - Miami
- Central Florida Pulmonary - Orlando
California
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California Davis Medical Center - Sacramento
Missouri
- Blessing Corporate Services, Inc., dba Blessing Health System - Hannibal
- Cardinal Glennon Children's Hospital - St. Louis University - St Louis
North Carolina
- University of North Carolina Medical Center - Chapel Hill
- Wake Forest University Baptist Medical Center - Winston-Salem
Texas
- Renovatio Clinical - Houston
- The University of Texas Health Science Center at Tyler - Tyler
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- National Jewish Health - Denver
Iowa
- The University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-07-24 |
| Est. Completion | 2021-05-04 |
| Phase | Phase 2 |
What the finished NCT04474197 record still lists
NCT04474197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 2,340-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04474197 names 20 study sites across 14 states, led by Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04474197 about?
NCT04474197 is a clinical study titled "Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype". This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
What is the current status of trial NCT04474197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2020-07-24. Estimated completion is 2021-05-04.
What conditions does trial NCT04474197 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT04474197?
The interventions under investigation include: Placebo (DRUG), VX-864 (DRUG).
Who is sponsoring clinical trial NCT04474197?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474197 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04474197's enrollment target sits among peer trials
44 14th of 24 higher than 11 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
COMPLETED · Phase 2
-
Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
COMPLETED · Phase 2
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI